Biocompatibles adds technology platform and two licences
This article was originally published in Clinica
Executive Summary
Biocompatibles, a darling of the UK stock market since its entry into the stent market late last year, has added a new technology platform and two new licences to its own coatings know-how based on phosphorylcholine (PC). Together with its 1996 results, it also reported that it launched its DivYsio stent in selected markets in February. The company's shares doubled since its share issue last November, closing at £10.90 on March 26th.
You may also be interested in...
PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
Biden Aims For 200 Mil. More COVID Vaccine Doses As Nervous Europe Eyes Its Borders
Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.
Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight
Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: